Login to Your Account

With FDA all-clear, Soligenix to move oral mucositis candidate into pivotal study

By Marie Powers
News Editor

Wednesday, May 3, 2017

After a year of gathering feedback from regulators following completion of its phase II study, Soligenix Inc. said it reached accord with the FDA to advance SGX-942 into a pivotal phase III study to treat oral mucositis in head and neck cancer patients treated with chemoradiation.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription